Core Insights - Viking Therapeutics (VKTX) has completed enrollment for its VANQUISH-1 study focused on VK2735 in obesity and is on track to finish enrollment for the VANQUISH-2 study in type 2 diabetes/obesity within the current quarter [1] Group 1 - The VANQUISH-1 study will take a total of 78 weeks to complete [1] - The VANQUISH-2 study is specifically targeting type 2 diabetes in conjunction with obesity [1]

Core Insights - The article emphasizes the importance of understanding the science behind biotech investments to avoid potential pitfalls in the industry [1]. Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies [1]. - The mission is to educate investors on the scientific aspects of biotech businesses to facilitate informed decision-making [1].